Effect of Vildagliptin vs. Metformin on hepatic steatosis in type 2 diabetic patients

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Emergency Medicine
Internal/Family Medicine
Surgery
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Thumbnail image
Detail Image
Detailed image
Book Detail
Upload PDF
Drug Updates issue 30Jan2025 -Shalina Medspace.pdf (117.2 KB)
Promotional Categories
Featured
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

In 246 newly diagnosed T2D patients, both vildagliptin and metformin improved glycaemic control (reduced FBG, HbA1c) and decreased HSI, body weight, and BMI, with metformin having a stronger effect on weight/BMI. Both drugs reduced hepatic steatosis, with total cholesterol and LDL as key predictors.

Published Date